HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

Ruihua Zhao, Jordan M. Chinai, Susan Buhl, Lisa Scandiuzzi, Anjana Ray, Hyungjun Jeon, Kim C. Ohaegbulam, Kaya Ghosh, Aimin Zhao, Matthew D. Scharff, Xingxing Zang

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

T-cell costimulation and coinhibition generated by engagement of the B7 family and their receptor CD28 family are of central importance in regulating the T-cell response, making these pathways very attractive therapeutic targets. Here we describe HERV-H LTR-associating protein 2 (HHLA2) as a member of the B7 family that shares 10-18% amino acid identity and 23-33% similarity to other human B7 proteins and phylogenetically forms a subfamily with B7x and B7-H3 within the family. HHLA2 is expressed in humans but not in mice, which is unique within the B7 and CD28 families. HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ. HHLA2 does not interact with other known members of the CD28 family or the B7 family, but does bind a putative receptor that is constitutively expressed not only on resting and activated CD4 and CD8 T cells but also on antigen-presenting cells. HHLA2 inhibits proliferation of both CD4 and CD8 T cells in the presence of T-cell receptor signaling. In addition, HHLA2 significantly reduces cytokine production by T cells including IFN-γ, TNF-α, IL-5, IL-10, IL-13, IL-17A, and IL-22. Thus, we have identified a unique B7 pathway that is able to inhibit human CD4 and CD8 T-cell proliferation and cytokine production. This unique human T-cell coinhibitory pathway may afford unique strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may help to design better vaccines.

Original languageEnglish (US)
Pages (from-to)9879-9884
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number24
DOIs
StatePublished - Jun 11 2013

Fingerprint

Endogenous Retroviruses
T-Lymphocytes
Proteins
Cytokines
Interleukin-13
Interleukin-17
Interleukin-5
Graft Rejection
Antigen-Presenting Cells
T-Cell Antigen Receptor
Interleukin-10
Monocytes
B-Lymphocytes
Vaccines
Cell Proliferation
Amino Acids

ASJC Scopus subject areas

  • General

Cite this

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. / Zhao, Ruihua; Chinai, Jordan M.; Buhl, Susan; Scandiuzzi, Lisa; Ray, Anjana; Jeon, Hyungjun; Ohaegbulam, Kim C.; Ghosh, Kaya; Zhao, Aimin; Scharff, Matthew D.; Zang, Xingxing.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 24, 11.06.2013, p. 9879-9884.

Research output: Contribution to journalArticle

Zhao, Ruihua ; Chinai, Jordan M. ; Buhl, Susan ; Scandiuzzi, Lisa ; Ray, Anjana ; Jeon, Hyungjun ; Ohaegbulam, Kim C. ; Ghosh, Kaya ; Zhao, Aimin ; Scharff, Matthew D. ; Zang, Xingxing. / HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 24. pp. 9879-9884.
@article{1fce6a7cbb1843d4aa00deb55ce67712,
title = "HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function",
abstract = "T-cell costimulation and coinhibition generated by engagement of the B7 family and their receptor CD28 family are of central importance in regulating the T-cell response, making these pathways very attractive therapeutic targets. Here we describe HERV-H LTR-associating protein 2 (HHLA2) as a member of the B7 family that shares 10-18{\%} amino acid identity and 23-33{\%} similarity to other human B7 proteins and phylogenetically forms a subfamily with B7x and B7-H3 within the family. HHLA2 is expressed in humans but not in mice, which is unique within the B7 and CD28 families. HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ. HHLA2 does not interact with other known members of the CD28 family or the B7 family, but does bind a putative receptor that is constitutively expressed not only on resting and activated CD4 and CD8 T cells but also on antigen-presenting cells. HHLA2 inhibits proliferation of both CD4 and CD8 T cells in the presence of T-cell receptor signaling. In addition, HHLA2 significantly reduces cytokine production by T cells including IFN-γ, TNF-α, IL-5, IL-10, IL-13, IL-17A, and IL-22. Thus, we have identified a unique B7 pathway that is able to inhibit human CD4 and CD8 T-cell proliferation and cytokine production. This unique human T-cell coinhibitory pathway may afford unique strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may help to design better vaccines.",
author = "Ruihua Zhao and Chinai, {Jordan M.} and Susan Buhl and Lisa Scandiuzzi and Anjana Ray and Hyungjun Jeon and Ohaegbulam, {Kim C.} and Kaya Ghosh and Aimin Zhao and Scharff, {Matthew D.} and Xingxing Zang",
year = "2013",
month = "6",
day = "11",
doi = "10.1073/pnas.1303524110",
language = "English (US)",
volume = "110",
pages = "9879--9884",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "24",

}

TY - JOUR

T1 - HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

AU - Zhao, Ruihua

AU - Chinai, Jordan M.

AU - Buhl, Susan

AU - Scandiuzzi, Lisa

AU - Ray, Anjana

AU - Jeon, Hyungjun

AU - Ohaegbulam, Kim C.

AU - Ghosh, Kaya

AU - Zhao, Aimin

AU - Scharff, Matthew D.

AU - Zang, Xingxing

PY - 2013/6/11

Y1 - 2013/6/11

N2 - T-cell costimulation and coinhibition generated by engagement of the B7 family and their receptor CD28 family are of central importance in regulating the T-cell response, making these pathways very attractive therapeutic targets. Here we describe HERV-H LTR-associating protein 2 (HHLA2) as a member of the B7 family that shares 10-18% amino acid identity and 23-33% similarity to other human B7 proteins and phylogenetically forms a subfamily with B7x and B7-H3 within the family. HHLA2 is expressed in humans but not in mice, which is unique within the B7 and CD28 families. HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ. HHLA2 does not interact with other known members of the CD28 family or the B7 family, but does bind a putative receptor that is constitutively expressed not only on resting and activated CD4 and CD8 T cells but also on antigen-presenting cells. HHLA2 inhibits proliferation of both CD4 and CD8 T cells in the presence of T-cell receptor signaling. In addition, HHLA2 significantly reduces cytokine production by T cells including IFN-γ, TNF-α, IL-5, IL-10, IL-13, IL-17A, and IL-22. Thus, we have identified a unique B7 pathway that is able to inhibit human CD4 and CD8 T-cell proliferation and cytokine production. This unique human T-cell coinhibitory pathway may afford unique strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may help to design better vaccines.

AB - T-cell costimulation and coinhibition generated by engagement of the B7 family and their receptor CD28 family are of central importance in regulating the T-cell response, making these pathways very attractive therapeutic targets. Here we describe HERV-H LTR-associating protein 2 (HHLA2) as a member of the B7 family that shares 10-18% amino acid identity and 23-33% similarity to other human B7 proteins and phylogenetically forms a subfamily with B7x and B7-H3 within the family. HHLA2 is expressed in humans but not in mice, which is unique within the B7 and CD28 families. HHLA2 protein is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation with LPS and IFN-γ. HHLA2 does not interact with other known members of the CD28 family or the B7 family, but does bind a putative receptor that is constitutively expressed not only on resting and activated CD4 and CD8 T cells but also on antigen-presenting cells. HHLA2 inhibits proliferation of both CD4 and CD8 T cells in the presence of T-cell receptor signaling. In addition, HHLA2 significantly reduces cytokine production by T cells including IFN-γ, TNF-α, IL-5, IL-10, IL-13, IL-17A, and IL-22. Thus, we have identified a unique B7 pathway that is able to inhibit human CD4 and CD8 T-cell proliferation and cytokine production. This unique human T-cell coinhibitory pathway may afford unique strategies for the treatment of human cancers, autoimmune disorders, infection, and transplant rejection and may help to design better vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84878990597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878990597&partnerID=8YFLogxK

U2 - 10.1073/pnas.1303524110

DO - 10.1073/pnas.1303524110

M3 - Article

C2 - 23716685

AN - SCOPUS:84878990597

VL - 110

SP - 9879

EP - 9884

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 24

ER -